Long-Term Clinical Outcomes in Hcv Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin: First Interim Safety and Efficacy Results from Topaz-I
67Th Annual Meeting of the American-Association-For-The-Study-Of-Liver-Diseases (Aasld), Date: NOV 11-15, 2016, Location: Boston, MA, Patrocinadores: Amer Assoc Study Liver Dis
